mAbxience News and Resources

mAbxience, a majority-owned company of Fresenius Kabi and partially owned by Insud Pharma, has announced a new strategic licensing agreement with Corapharm to develop and commercialise a biosimilar candidate in Southeast Europe. Under the terms of the agreement, mAbxience will retain marketing

mAbxience, a Fresenius Kabi majority-owned CDMO with additional ownership from Insud Pharma, has entered a strategic licensing agreement with Italy-based Abiogen Pharma to develop and commercialise a biosimilar product in the Italian market. Under the terms of the agreement, mAbxience will hold

Amneal Pharmaceuticals, Inc. and mAbxience have received FDA acceptance for the review of their Biologics License Application (BLA) for two proposed denosumab biosimilars, referencing Prolia and XGEVA. The FDA has assigned a target action date in the fourth quarter of 2025. Denosumab is

mAbxience, partly owned by Fresenius Kabi and Insud Pharma, has entered a strategic agreement with Egis Pharmaceutical PLC to commercialise two biosimilar candidates in Central and Eastern Europe. The partnership encompasses eight countries: Hungary, Poland, Czech Republic, Slovakia, Romania, Bulgaria,

mAbxience, a company in the pharmaceutical industry, has announced the appointment of Jurgen Van Broeck as its new Chief Executive Officer. Broeck, who has been serving as the Global Commercial Director since June 2023, is set to bring his wealth

Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd., and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, have announced a strategic licensing agreement for a biosimilar candidate currently in development for the treatment